JP2015519402A - Ｐｄｅ１０阻害剤として有用なアゼチジンおよびピペリジン化合物 - Google Patents

Ｐｄｅ１０阻害剤として有用なアゼチジンおよびピペリジン化合物 Download PDF

Info

Publication number
JP2015519402A
JP2015519402A JP2015517445A JP2015517445A JP2015519402A JP 2015519402 A JP2015519402 A JP 2015519402A JP 2015517445 A JP2015517445 A JP 2015517445A JP 2015517445 A JP2015517445 A JP 2015517445A JP 2015519402 A JP2015519402 A JP 2015519402A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015517445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519402A5 (enExample
Inventor
アレン，ジェニファー・アール
チェン，ジエン・ジェイ
フローン，マイケル・ジェイ
カラー，マシュー・リチャード
リウ，チンイエン
グエン，トーマス・ティー
ピックレル，アレクサンダー・ジェイ
チエン，ウエンユエン
ルザサ，ロバート・エム
ジョン，ウェンジ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48692687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015519402(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2015519402A publication Critical patent/JP2015519402A/ja
Publication of JP2015519402A5 publication Critical patent/JP2015519402A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
JP2015517445A 2012-06-14 2013-06-14 Ｐｄｅ１０阻害剤として有用なアゼチジンおよびピペリジン化合物 Pending JP2015519402A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659911P 2012-06-14 2012-06-14
US61/659,911 2012-06-14
PCT/US2013/045768 WO2013188724A1 (en) 2012-06-14 2013-06-14 Azetidine and piperidine compounds useful as pde10 inhibitors

Publications (2)

Publication Number Publication Date
JP2015519402A true JP2015519402A (ja) 2015-07-09
JP2015519402A5 JP2015519402A5 (enExample) 2016-07-28

Family

ID=48692687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517445A Pending JP2015519402A (ja) 2012-06-14 2013-06-14 Ｐｄｅ１０阻害剤として有用なアゼチジンおよびピペリジン化合物

Country Status (25)

Country Link
US (3) US8691986B2 (enExample)
EP (1) EP2864317A1 (enExample)
JP (1) JP2015519402A (enExample)
KR (1) KR20150023417A (enExample)
CN (1) CN104619694A (enExample)
AP (1) AP2014008136A0 (enExample)
AR (1) AR091436A1 (enExample)
AU (1) AU2013274153B2 (enExample)
BR (1) BR112014031368A2 (enExample)
CA (1) CA2875802A1 (enExample)
CL (1) CL2014003391A1 (enExample)
CO (1) CO7160011A2 (enExample)
CR (1) CR20150012A (enExample)
EA (1) EA201590014A1 (enExample)
HK (1) HK1203935A1 (enExample)
IL (1) IL235901A0 (enExample)
MA (1) MA37748B1 (enExample)
MX (1) MX2014014924A (enExample)
PE (1) PE20150348A1 (enExample)
PH (1) PH12014502780A1 (enExample)
SG (1) SG11201408168UA (enExample)
TN (1) TN2014000510A1 (enExample)
TW (1) TWI508959B (enExample)
UY (1) UY34858A (enExample)
WO (1) WO2013188724A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012013130A (es) 2010-05-13 2013-04-11 Amgen Inc Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10.
UY34858A (es) * 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143365A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US8497265B2 (en) * 2010-05-13 2013-07-30 Amgen Inc. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
MX2012013128A (es) * 2010-05-13 2013-03-20 Amgen Inc Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10.
WO2011143366A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
UY34858A (es) * 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143365A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors

Also Published As

Publication number Publication date
MX2014014924A (es) 2015-03-09
MA37748A1 (fr) 2016-11-30
CO7160011A2 (es) 2015-01-15
PH12014502780A1 (en) 2015-02-02
EA201590014A1 (ru) 2015-04-30
AR091436A1 (es) 2015-02-04
US9303028B2 (en) 2016-04-05
CA2875802A1 (en) 2013-12-19
PE20150348A1 (es) 2015-03-04
WO2013188724A1 (en) 2013-12-19
US9493459B2 (en) 2016-11-15
HK1203935A1 (en) 2015-11-06
US8691986B2 (en) 2014-04-08
US20160176874A1 (en) 2016-06-23
AU2013274153B2 (en) 2016-05-19
TN2014000510A1 (en) 2016-03-30
IL235901A0 (en) 2015-09-24
US20140148435A1 (en) 2014-05-29
US20130338138A1 (en) 2013-12-19
SG11201408168UA (en) 2015-01-29
BR112014031368A2 (pt) 2017-06-27
EP2864317A1 (en) 2015-04-29
TWI508959B (zh) 2015-11-21
AP2014008136A0 (en) 2014-12-31
CR20150012A (es) 2015-02-11
AU2013274153A1 (en) 2014-12-18
KR20150023417A (ko) 2015-03-05
MA37748B1 (fr) 2017-07-31
CN104619694A (zh) 2015-05-13
TW201412729A (zh) 2014-04-01
UY34858A (es) 2013-11-29
CL2014003391A1 (es) 2015-07-10

Similar Documents

Publication Publication Date Title
JP5702855B2 (ja) Ｐｄｅ１０阻害剤として有用な窒素複素環化合物
JP5546693B2 (ja) ピラゾロキノリン誘導体
ES2527216T3 (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima PDE10A
ES2514647T3 (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de la enzima PDE10A
JP2013526524A (ja) Ｐｄｅ１０阻害剤としてのアリールおよびヘテロアリール窒素ヘテロ環式化合物
US20130131039A1 (en) 5,7-substituted-imidazo[1,2-c]pyrimidines as inhibitors of jak kinases
ES2442179T3 (es) Derivados heteroaromáticos de aril-triazoles como inhibidores de la enzima PDE10A
EA019941B1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
EA018880B1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
EP3694330B1 (en) Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP4161927B9 (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
EA027082B1 (ru) Производные имидазола в качестве ингибиторов фермента pde10a
US20240228469A1 (en) Pcsk9 inhibitors and methods of use thereof
US9493459B2 (en) Azetidine and piperidine compounds useful as PDE10 inhibitors
EP3269714A1 (en) Inhibitors of tryptophan 2,3-dioxygenase
EA049416B1 (ru) Ингибиторы аутофагии на основе гетероариламинопиримидинамида и способы их применения
HK1195498A (en) 1,5-naphthyridine derivatives as melk inhibitors
HK1195498B (en) 1,5-naphthyridine derivatives as melk inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160606

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171010